Browsing by Author "Bhalla, K N"
Now showing items 1-2 of 2
-
Phase ia/ii, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
DeAngelo, D J; Spencer, A; Bhalla, K N; Prince, H M; Fischer, T; Kindler, T; Giles, F J; Scott, J W; Parker, K; Liu, A; Woo, M; Atadja, P; Mishra, K K; Ottmann, O G (Springer Nature, 2013-02-06)Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to ... -
Prediction of outcomes in patients with ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
Jabbour, E; le Coutre, P D; Cortes, J; Giles, F; Bhalla, K N; Pinilla-Ibarz, J; Larson, R A; Gattermann, N; Ottmann, O G; Hochhaus, A; Hughes, T P; Saglio, G; Radich, J P; Kim, D-W; Martinelli, G; Reynolds, J; Woodman, R C; Baccarani, M; Kantarjian, H M (Springer Nature, 2012-11-06)The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intolerant patients ...